Sutent is so well established as the favorable 1st line in RCC and very potent in this setting that I think it would be a mission impossible for Onyx to make inroads in kidney cancer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.